Doug Ward has more than 30 years of biotech and medical technology experience at notable global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic. Mr. Ward was named CEO of Lumos Diagnostics in June 2022 and is looking forward to leveraging his industry experience to guide Lumos Diagnostics through an exciting time of unlimited potential growth.

During his career, Mr. Ward has held executive positions where he developed and implemented novel business strategies and introduced transformational products to the practice of medicine. Prior to joining Lumos, he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in women’s healthcare to improve clinical results. Mr. Ward also served as the CEO of Personal Genome Diagnostics (PGDx) where he led the organization’s transformation from a clinical laboratory testing service into a fully functional molecular invitro diagnostics (IVD) company. 

With a deep understanding of the life sciences ecosystem, Mr. Ward excels at setting the strategic direction for global companies. He brings experience across all company functions, including Commercial Leadership, R&D, Operations, Quality, Regulatory, Service, and Support.

Mr. Ward earned his Bachelor of Arts in Pre-medicine Studies from Ohio Wesleyan University. 

Sacha Dopheide, PhD has more than 15 years of experience in the in vitro diagnostic device industry, ranging from point-of-care devices to laboratory analyzers. She currently serves as the company’s Chief Technology Officer and has held an executive leadership role within Lumos Diagnostics since its acquisition of Kestrel Bioscience in 2017. Dr. Dopheide has experience managing the full range of product development for both immunoassays and their accompanying electronic readers from proof of concept through development, verification and external validation trials. Dr. Dopheide has taken a leading role in identification and due diligence of M&A targets and integration activities. She also leads the Lumos Diagnostic service business unit’s business development activities, including directly conducting global market research, establishing partnerships and generating strategic product roadmaps for new tests.

Dr. Dopheide holds a BSc with First Class Honours in Biochemistry and Molecular Biology from Monash University. She received her PhD in Medicine in 2000, for which she was awarded the Victoria Fellowship for Excellence in Medical Research.

Barrie Lambert has more than 20 years of international experience in high growth companies from the medical device research and development services and manufacturing sector, as well as technology, retail, ecommerce, consumer goods and business services. Prior to joining Lumos Diagnostics, Mr. Lambert was the Chief Financial Officer of Planet Innovation, one of the founding shareholders and current major shareholder of Lumos. In that role, he was a member of the executive team helping to grow Planet Innovation fourfold, completing several capital raises, financing, and merger and acquisition transactions.

Mr. Lambert’s previous roles have included Chief Financial Officer and President & Chief Executive Officer of technology businesses with operations in Australia, United States, New Zealand and United Kingdom. He also spent more than six years as Chief Financial Officer, Vice President of Operations, then as the Vice President and General Manager of Sephora.com, a business unit of Louis Vuitton Moet Hennessy.

Mr. Lambert has a broad background in governance, strategy, finance, M&A, operations, technology and sales, which have allowed him to drive positive change by partnering with the Executive Team and Board of Directors to set and execute strategy, deliver quality customer service and create value. His qualifications include a BA in Accounting from the University of South Australia, Chartered Accountant from the Australian Institute of Chartered Accountants, MBA from the Graduate School of Business, University of Sydney, and a graduate of the Australian Institute of Company Directors.

Paul Kase brings more than 28 years of medical sales and leadership experience in the point-of-care diagnostic testing market to Lumos Diagnostics. As the Senior Vice President of Commercial Operations, he is responsible for leading worldwide commercial sales efforts, while implementing marketing strategies focused on revenue growth, building strong customer partnerships, and generating end-user demand and adoption for a portfolio of products. 

Mr. Kase is a proven leader in coaching and developing best-in-class sales teams that consistently meet and exceed revenue goals. His experience also extends to overseeing customer and technical support divisions, commercial product launches, key opinion leader development, and the creation of distributor networks in the hospital and primary care markets.

Mr. Kase earned his Bachelors in Economics and English from Bucknell University.

Anthony Favaloro has more than 15 years of experience working in design, sales, and operational roles within the invitro diagnostics and medical device industry. He currently serves as the Vice President of Business Operations at Lumos Diagnostics.

Mr. Favaloro has a demonstrated track record in establishing and fostering successful partnerships through a combination of technical expertise and commercial acumen. He has experience leading large, multi-disciplinary teams to conceptualize commercially viable, patentable core technology through development, clinical studies, regulatory submissions, and post-launch support. His methods focus on creating value for internal and external stakeholders.

Mr. Favaloro earned an Honours degree in Electrical Engineering and a Bachelor of Biomedical Science majoring in Biochemistry and Physiology from The University of Melbourne.

Kepa Oyarbide has more than 16 years of professional experience in R&D and technical operations, specializing in product development and technology transfer. He currently serves as the Vice President of Manufacturing Operations after holding senior positions in technology transfer, where he played a significant role in the development of numerous immunoassay applications for both internal projects and inter-firm transfer models. Mr. Oyarbide oversees the planning and organization of our production processes and assists in securing materials and other resources by leveraging partnerships with key stakeholders and industry associations. He has a passion for people-first leadership, encouraging innovation and entrepreneurship in his team, as well as promoting inter-departmental collaboration for effective problem-solving.

Before joining Lumos, Mr. Oyarbide served as Director of Research and Development for NuGenerex Diagnostics and HEMA Diagnostic Systems in Miramar, FL. He holds a Master’s in Molecular Biology from Loyola University in Chicago.

Sue Hibbeln has more than 15 years in Regulatory Affairs and Quality Assurance at start-up, mid- and large-sized companies for a variety of medical devices, including in vitro diagnostic devices, software, hardware, implants and sutures. She currently serves as the company’s Vice President of Quality and Regulatory Affairs. Ms. Hibbeln specializes in global strategy, registration, regulatory/cultural intelligence and quality systems.

Her passion for working with diverse cultures has enabled opportunities to work with world-class talent on global cross-functional teams. Ms. Hibbeln especially enjoys helping clients with global remediation and harmonization efforts and monitors direction from the International Medical Device Regulators Forum (IMDRF). Ms. Hibbeln is a CMMI Associate and a certified appraisal team member (ATM) for the Medical Device Discovery Appraisal Program (MDDAP) – a joint initiative for FDA, MDIC, and CMMI.

Ms. Hibbeln earned a BA from LaSalle University, an MS in Regulatory Affairs from San Diego State University and a Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professionals Society (RAPS). She also completed the Kellogg Executive Leadership Program at Northwestern University.

Sarah Glubka has more than 17 years of experience in human resources and currently serves as the company’s Senior Director of Human Resources.

Ms. Glubka most recently served as the Director of Human Resources for Australia-based Planet Innovation where she developed business initiatives, fostered employee engagement and mobilized talent. She was a key strategic business partner for the global product and service organization; working collaboratively with the leadership team and board of directors to establish strategies to ensure staff engagement. Ms. Glubka also championed, designed and implemented a successful company-wide employee health and safety program. Prior to Planet Innovation, Ms. Glubka was the Supervisor of Administrative Services for Kaiser Permanente where she developed payroll and attendance reports, metrics and analytics to support business needs and increase efficiencies. She also has expertise establishing human resource infrastructures for U.S. entities, including policies, standardized processes and procedures, and documentation to ensure compliance with all state and federal regulations as well as provide consistency in practice across the company.  

Ms. Glubka earned a BS in Business Management from the University of Phoenix.

Annie Bell has more than 15 years of professional experience in the medical device and in vitro diagnostic industry including direct patient management, medical education and clinical study management. Currently serving as the Director of Medical Affairs for Lumos Diagnostics, Ms. Bell is a strategic leader with a passion for improving patient lives through early detection of disease. She has expertise in the initiation and oversight of clinical trials including FDA registration trials.

Ms. Bell holds a BS in Nursing from Pennsylvania State University, an MS in Nursing from Rush University Chicago, IL, and is a graduate of the Global Clinical Trials Clinical Research Program, Harvard Medical School, Boston MA. In addition, Ms. Bell is a Board-certified Neonatal Nurse Practitioner.